[Federal Register Volume 81, Number 3 (Wednesday, January 6, 2016)]
[Notices]
[Page 513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-33266]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--National Chemical & Biological Defense
Consortium
Notice is hereby given that, on November 13, 2015, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), National Chemical &
Biological Defense Consortium (``NCBDC'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing (1) the identities of the parties to the
venture and (2) the nature and objectives of the venture. The
notifications were filed for the purpose of invoking the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances.
Pursuant to section 6(b) of the Act, the identities of the parties
to the venture are: AbViro LLC, Bethesda, MD; Advanced Nuclear Devices
Corporation, Hilton Head Island, SC; Aequor, Inc., Oceanside, CA;
Aeterna Zentaris, Qu[eacute]bec, CANADA; AIBiotech, Richmond, VA;
Allied Technologies & Consulting, LLC, Frederick, MD; AMH Consulting,
Potomac, MD; AntibioTx ApS, H[oslash]rsholm, DENMARK; Approach
Robotics, Ridgecrest, CA; Aradigm Corporation, Hayward, CA; Artificial
Cell Technologies, Inc., New Haven, CT; BalinBac Therapeutics, Inc.,
Princeton, NJ; Battelle Memorial Institute, Columbus, OH; BioFactura,
Inc., Frederick, MD; BioStat Solutions, Inc., Frederick, MD; Burrell
International Group, LLC, Frederick, MD; CACI, Arlington, VA; CFD
Research Corporation, Huntsville, AL; CONTINUUS Pharmaceuticals, Inc.,
Woburn, MA; Creare LLC, Hanover, NH; CSC Government Solutions LLC,
Falls Church, VA; CUBRC, Inc., Buffalo, NY; DALI Medical Devices Ltd.,
Yavne, ISRAEL; Design West Technologies Inc., Tustin, CA; Draper
Laboratory, Cambridge, MA; Eagle Applied Science, San Antonio, TX;
Emergent, Inc., North Charleston, SC; Equivital Inc., New York, NY; EZ-
A Consulting, LLC, Bel Air, MD; First Line Technology, Chantilly, VA;
General Dynamics Information Technology, San Diego, CA; GeoVax Labs,
Inc., Smyrna, GA; Ginkgo BioWorks, Boston, MA; Goldbelt Raven, LLC,
Herndon, VA; Hackensack University Medical Center, Hackensack, NJ;
iBio, Inc., New York, NY; IIT Research Institute, Chicago, IL; Immune
Biosolutions, Inc., Qu[eacute]bec, CANADA; Inficon, East Syracuse, NY;
Integrated BioTherapeutics, Inc., Gaithersburg, MD; InvivoSciences
Inc., Madison, WI; Jade Therapeutics, Inc., Salt Lake City, UT; JRAD,
Stafford, VA; KD Analytical, Harrisburg, PA; Kestrel Corporation,
Albuquerque, NM; Kinnear Pharmaceuticals, LLC, Columbus, OH; Kiyatec,
Greenville, SC; L-3 Communications, New York, NY; Latham BioPharm
Group, Inc., Maynard, MA; Luminex Corporation, Austin, TX; MainStream
Global Solutions, Robins, IA; Mapp Biopharmaceutical, Inc., San Diego,
CA; MaxCyte, Inc., Gaithersburg, MD; Med-Ally, Canton, CT; MedPro
Technologies, LLC, San Antonio, TX; Mesa Science Associates Inc.,
Frederick, MD; Michael T. Brown Consulting, LLC, Austin, TX; Microbial
Robotics, LLC, Covington, KY; Mike Sellers & Associates, Beavercreek,
OH; MLT Systems, Stafford, VA; MRI Global, Kansas City, MO;
Nanotherapeutics, Inc., Alachua, FL; New York Blood Center Inc., New
York, NY; Novici Biotech LLC, Vacaville, CA; Novozymes, Inc.,
Franklinton, NC; OrPro Therapeutics, Inc., San Diego, CA; Parsons,
Washington, DC; Pertexa, Ridgecrest, CA; Philips, Foster City, CA; PrEP
Biopharm, Rumson, NJ; Purdue University, West Lafayette, IN;
QuickSilver Analytics, Belcamp, MD; Quintiles, Durham, NC; Rapid
Pathogen Screening, Inc. (RPS), Sarasota, FL; Recursion
Pharmaceuticals, Salt Lake City, UT; RTI International, Coraopolis, PA;
San Diego State University, San Diego, CA; Science Applications
International Corporation, McLean, VA; SciTech Services Inc., Havre De
Grace, MD; Shield Analysis Technology, LLC, Manassas, VA; SIGA
Technologies, Inc., New York, NY; Signature Science, Austin, TX; Smart
Consulting Group, LLC, West Chester, PA; Southern Research Institute,
Birmingham, AL; Southwest Research Institute, San Antonio, TX; Spero
Therapeutics, Cambridge, MA; SRI International, Princeton, NJ;
Strategic Solutions Integrated, Arlington, VA; TDA Research, Inc.,
Wheat Ridge, CO; Tetracore, Inc., Rockville, MD; Texas A&M, Bryan, TX;
TheraSource LLC, Roslyn, NY; Trideum, Huntsville, AL; TriLink
BioTechnologies, San Diego, CA; Ubiquitome Limited, Auckland, NEW
ZEALAND; University of Florida Institute for Therapeutic Innovation,
Gainesville, FL; University of Nebraska Medical Center--Department of
Pathology and Microbiology, Omaha, NE; University of North Texas Health
Sciences Center, Fort Worth, TX; University of Pittsburgh--Center for
Military Medicine Research, Pittsburgh, PA; and Vaxess Technologies,
Inc., Cambridge, MA. The general area of NCBDC's planned activity is
advanced development efforts to support the Department of Defense's
medical pharmaceutical and diagnostic requirements as related to
enhancing the mission effectiveness of military personnel through (i)
detection--systems and devices to identify CBRN (Chemical Biological
Radiological and Nuclear) agents and assist in making medical
decisions; (ii) prevention--prophylaxis, pretreatment, and post-
exposure prophylaxis; (iii) treatment--therapeutics (post-exposure,
post-symptomatic); and (iv) chemical--medical protection against use of
chemical agents.
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2015-33266 Filed 1-5-16; 8:45 am]
BILLING CODE P